Related Experiment Video
Updated: Aug 30, 2026
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
New retinoblastoma tumor formation in children initially treated with systemic carboplatin
Thomas C Lee1, Naomi I Hayashi, Ira J Dunkel
1Department of Ophthalmology, New York-Presbyterian Hospital-Weill Medical College of Cornell University, 70 East 66th Street, New York, NY 10021, USA.
Purpose:
To determine the frequency and timing of new intraocular tumor formation in children with hereditary retinoblastoma initially treated with systemic carboplatin.
Design:
Retrospective, noncomparative case series.
Participants:
This study included 34 children (57 eyes) with hereditary bilateral retinoblastoma initially treated with systemic carboplatin at the Robert M. Ellsworth Ophthalmic Oncology Center at NewYork-Presbyterian Hospital from 1994 through 2000.
Main Outcome Measures:
New tumor formation after initial treatment with systemic carboplatin.
Results:
There were a total of 165 tumors in 57 eyes. There were 63 new tumors in 27 eyes (47%) after administration of systemic carboplatin, for a mean of 1.1 new tumors per eye. The mean patient age at time of new tumor presentation was 9 months, with 57% of new tumors developing within 4 months of carboplatin treatment. Kaplan-Meier analysis showed that children who were treated when younger than 6 months of age were more likely to have new tumors (60%) compared with those treated after 6 months of age (31%; P = 0.0182).
Conclusions:
New intraocular tumors continue to develop after systemic carboplatin; most new tumors appeared within 4 months of treatment.
